Cell therapy

MRI showing glioblastoma
#Brain cancer #CAR-T #Cell therapy #Oncology #University of Pennsylvania

‘Dual-target’ CAR-T cell therapy shrinks brain tumours

Targeting two brain tumour-associated proteins – rather than one – with CAR-T cell therapy has shown promise as a strategy for reducing solid tumour growth in patients with recurrent glioblastoma (GBM). This is according to early results from the first six patients treated in an ongoing… Read More

#Cancer Research #News

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Cell therapy #CHMP #European Medicines Agency #Myeloma #Oncology

CAR-T therapy recommended for melanoma after first relapse

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM). The recommended indication for cilta-cel is for the treatment of… Read More

#News #Regulatory

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

New DDW Highlights podcast: 26 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a breakthrough for advanced therapies, this week saw the FDA approve the first… Read More

#News

Cells under a microscope
#bit bio #CAR-T #Cell therapy #Interview #iPSC #Stem cells

Scaling up: The need for human cells to give better access to cell therapies

Reece Armstrong speaks to Kathryn Golden, SVP Technical Operations and Manufacturing, bit.bio, about novel technologies, and methods to manufacture human cells for therapies so more patients can access these treatments. Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas. These therapies, which utilise… Read More

#Exclusive Content

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

This week in drug discovery (19-23 February) 

News round-up for 19-23 February by DDW Digital Content Editor Diana Spencer. In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. The… Read More

#News

#Astellas Pharma #CAR-T #Cell therapy #Collaboration #Immuno-oncology #In vivo #Kelonia Therapeutics #Xyphos Biosciences

Companies agree $800m deal for in vivo CAR-T cell therapy

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Kevin… Read More

#Business & Investment #News #Trending News

#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

The killer instinct: Using natural killer therapy to treat Alzheimer’s

DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech released data from its… Read More

#Exclusive Content

Diabetes patient injecting insulin
#allogeneic cell therapies #Cell therapy #Sana Biotechnology #Stem cell transplant #Type 1 diabetes

Insulin independence without immunosuppression

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). The study results were published in Cell Stem Cell, in a paper titled ‘Hypoimmune islets achieve insulin independence after allogeneic transplantation in a… Read More

#Editor's Choice #News

T cells attacking cancer
#Cell and gene therapy #Cell therapy #FDA #Iovance #Melanoma #Oncology #Solid tumours

FDA approves first T cell therapy in solid tumours

The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or… Read More

#News #Regulatory #Trending News

CAR-T therapy
#CAR-T #Cell and gene therapy #Cell therapy #Immunotherapy #Kyverna Therapeutics #Oncology

Novel CAR T-cell vein-to-vein process could reduce time and cost

A paper in BioRxiv has described a new process that could improve the chimeric antigen receptor (CAR) T-cell patient experience and reduce costs through a minimisation of the CAR T-cell therapy vein-to-vein process. The process utilises less than 300ml of whole blood from a blood draw… Read More

#Cancer Research #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

Stem cell transplant
#Cell therapy #Pluripotent stem cells #Regenerative Medicine #Stem cell transplant #Stem cells #University of Arizona

Genetically modified stem cells evade immune rejection

New research has brought stem cell transplantation without immune suppression closer to reality. Researchers at the University of Arizona Health Sciences say they are one step closer to understanding immunological rejection, a barrier to regenerative medicine, after genetically modifying pluripotent stem cells to evade immune recognition. Read More

#Editor's Choice #News

Cell and gene therapy
#Adverse event #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #FDA #Immunotherapy #ISCT #Oncology

Experts comment on FDA report on risk of T-cell malignancy  

The International Society for Cell & Gene Therapy (ISCT) has announced the publication in Nature Medicine of an expert consortium commentary addressing a recent statement from the US Food & Drug Administration (FDA) that it is investigating serious risk of T-cell malignancy in patients who received treatment with BCMA- or… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #Kyverna Therapeutics #Multiple sclerosis #Phase II trial

CAR-T therapy offers new hope to multiple sclerosis patients

Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in… Read More

#News